Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176202 · ClinicalTrials.gov registry record · Phase 3
Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar
A Phase 3 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
NCT00176202 is a Phase 3 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 65 participants.
The verdict
NCT00176202, a Phase 3 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
Study Summary
The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.
Interventions
- DRUG Divalproex Sodium
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2003-04 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176202
The ClinicalTrials.gov registry entry for NCT00176202 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Divalproex Sodium is the first listed.
NCT00176202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176202 about?
NCT00176202 is a clinical study titled "Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar". The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.
What is the current status of trial NCT00176202?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2003-04. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00176202?
The interventions under investigation include: Divalproex Sodium (DRUG), risperidone (DRUG).
Who is sponsoring clinical trial NCT00176202?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.